Company intelligence
Sequoia Genetics
Experts in leveraging genetic data for generating translational insights.
About Sequoia Genetics
Sequoia Genetics is dedicated to transforming genetic data into actionable insights. We work with life sciences investors, pharmaceutical and biotech companies to translate genetic evidence into drug discovery and drug development decisions. Our team is made up of biologists, clinicians, epidemiologists, statisticians, data scientists, bioinformaticians and industry experts that have collectively published hundreds of research papers in the field and are vastly experienced in translating genetic insights to guide clinical development decisions.
Verified activity
Signals from Sequoia Genetics
4 published signals
Partnerships
Sequoia Genetics is part of a British Chamber of Commerce trade accelerator in Singapore.
Reported by Dipender Gill
Research & Knowledge
Sequoia Genetics published the Alumis Phase 2b LUMUS study showing that Alumis did not meet its primary BICLA endpoint in the overall SLE population.
Reported by Dipender Gill
Research & Knowledge
Sequoia Genetics published the LUMUS results in systemic lupus erythematosus (SLE) showing that partial loss-of-function variants, including P1104A (rs34536443), are associated with lower disease risk and reduced TYK2-dependent signalling.
Reported by Dipender Gill
Research & Knowledge
Sequoia Genetics published the BMS Phase 2 PAISLEY study showing that deucravacitinib produced a Week-48 BICLA response in IFN gene-signature-high patients of approximately 51% with treatment vs 25% with placebo.
Reported by Dipender Gill